MedTrace Logo

A Two Week Nitazoxanidebased Quadruple Regimen

NCT02621359 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-01-03

No results posted yet for this study

Summary

Helicobacter pylori (H. pylori) infection is a global health problem as it is associated with peptic ulcers, chronic gastritis, duodenitis, and stomach cancer.

Therefore, the eradication of the pathogen is of critical importance to reduce H. pylori-related complications .

However, due to increasing antibiotic resistance, eradication of Helicobacter pylori has become more challenging. With a great decline in the eradication rate of standard triple therapy for Helicobacter pylori to below 70% in many countries.

Treatment with triple therapy, which is the most frequently recommended, fails to eradicate H. pylori in approximately 20% of cases .

Conditions

  • Dyspepsia

Interventions

DRUG

Nitazoxanide

Nitazoxanide 500 mg twice daily

DRUG

Levofloxacin

Levofloxacin 500 mg once daily

DRUG

Doxycyclin

Doxycyclin 100 mg twice daily

DRUG

Omeprazole

Omeprazole 40 mg twice daily

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Sherief Abd-Elsalam, lecturer · Tropical medicine-Tanta university hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02621359 on ClinicalTrials.gov